Home Online Features Apnimed Expands Portfolio of Oral Pharmacotherapies for Sleep and Breathing Diseases Through Acquisition of Global Rights to Patents Covering Sulthiame, a Differentiated Carbonic Anhydrase Inhibitor
Apnimed Expands Portfolio of Oral Pharmacotherapies for Sleep and Breathing Diseases Through Acquisition of Global Rights to Patents Covering Sulthiame, a Differentiated Carbonic Anhydrase Inhibitor
Hand-out
Press Releases
Apnimed, Inc.  
April 25, 2025

Apnimed Expands Portfolio of Oral Pharmacotherapies for Sleep and Breathing Diseases Through Acquisition of Global Rights to Patents Covering Sulthiame, a Differentiated Carbonic Anhydrase Inhibitor

- Apnimed and Shionogi will develop sulthiame within the Shionogi-Apnimed Sleep Science (SASS) Joint Venture for Obstructive Sleep Apnea (OSA) and other sleep-related breathing indications

logo salamanca press

Salamanca Press

email salamanca press
Local & Social